Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

26.63B

Market cap26.63B

Price-Earnings ratio

20.66

Price-Earnings ratio20.66

Dividend yield

—

Dividend yield—

Average volume

850.82K

Average volume850.82K

High today

$188.00

High today$188.00

Low today

$180.27

Low today$180.27

Open price

$185.99

Open price$185.99

Volume

1.09M

Volume1.09M

52 Week high

$202.41

52 Week high$202.41

52 Week low

$110.04

52 Week low$110.04

Stock Snapshot

Biogen(BIIB) stock is priced at $180.27, giving the company a market capitalization of 26.63B. It carries a P/E multiple of 20.66.

On 2026-03-14, Biogen(BIIB) stock moved within a range of $180.27 to $188.00. With shares now at $180.27, the stock is trading 0.0% above its intraday low and -4.1% below the session's peak.

Trading activity shows a volume of 1.09M, compared to an average daily volume of 850.82K.

Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $202.41 and a low of $110.04.

BIIB News

Simply Wall St 17h

Does New Once-Yearly SMA Data And Phase 3 Plan Change The Bull Case For Biogen?

In early March 2026, Biogen reported additional Phase 1b data for its investigational once-yearly SMA therapy salanersen, showing sustained safety, slowing of n...

Simply Wall St 2d

Assessing Biogen Valuation After Recent Shareholder Return Momentum

Advertisement What Biogen’s Recent Performance Signals for Investors Biogen (BIIB) has drawn attention after a mixed stretch, with the stock roughly flat over...

TipRanks 3d

Biogen Announces Upcoming Departure of Chief Legal Officer

Biogen ( (BIIB) ) has issued an update. On March 11, 2026, Biogen Inc. announced that its Chief Legal Officer, Susan H. Alexander, will leave the company at th...

Analyst ratings

56%

of 36 ratings

Buy

41.7%

Hold

55.6%

Sell

2.8%

More BIIB News

Simply Wall St 7d

Biogen’s Dravet And SMA Advances Add Depth To Long Term Story

Biogen (NasdaqGS:BIIB) and Stoke Therapeutics reported promising clinical results for zorevunersen in Dravet syndrome, with data highlighting durable seizure re...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Newly Listed

This list is generated by showing companies that recently went public.